ARDELIUS BOAN: Open Payments
NPI 1790147270 · STANFORD, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$992 in 50 payments from 9 companies in 2025. Trend: 2023 $0 · 2024 $1,107 · 2025 $992
Food & beverage: $992
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 19 | $446 |
| Neurocrine BioSciences, Inc. | 11 | $197 |
| PFIZER INC. | 10 | $140 |
| Lilly USA, LLC | 3 | $62 |
| JAZZ PHARMACEUTICALS INC. | 2 | $53 |
| Genentech USA, Inc. | 2 | $38 |
| UCB, Inc. | 1 | $19 |
| Amneal Pharmaceuticals LLC | 1 | $19 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
Products named: QULIPTA, INGREZZA, NURTEC ODT, BOTOX, KISUNLA, XYWAV, UBRELVY, Ocrevus Zunovo.
Industry payments across CA — which companies pay providers there.
